Explore original, structured summaries for research and education.
Research profile
Semaglutide(Ozempic)
Semaglutide(Ozempic) is indexed as a GLP-1 receptor agonist research entry. Its current evidence category is (Ozempic), and published discussion commonly places it within Weight Loss, Metabolic. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- 4,113.64 Da
- Chain length
- 31 amino acids
- Type
- GLP-1 receptor agonist
- Reported half-life
- ~7 days (168 hours)
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-GlyLiterature map
Research indications
Weight Loss
- Clinically Significant Weight Reductionmost effective
- Appetite and Craving Controlmost effective
- Sustained Weight Maintenanceeffective
Diabetes
- Glycemic Controlmost effective
- Cardiovascular Protectionmost effective
- Beta Cell Preservationeffective
Metabolic
- Metabolic Syndrome Improvementeffective
- NASH/Fatty Livermoderate
- Inflammation Reductionmoderate
Evidence-gated guidance
Dosing Protocols
A medicine-related record exists, but this profile does not yet contain an independently verified, jurisdiction-specific prescribing schedule. Use only the current authorized product label and a licensed clinician’s directions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for Semaglutide(Ozempic). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of Semaglutide(Ozempic) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is Semaglutide(Ozempic) approved for personal use?
An approved medicine-related record may exist, but approval depends on the exact active ingredient, product, indication, formulation, and country. Check the current local regulator and product label.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)Wilding, J.P.H., et al. · New England Journal of Medicine · 2021
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)Lincoff, A.M., et al. · New England Journal of Medicine · 2023
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)Marso, S.P., et al. · New England Journal of Medicine · 2016
- Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)Garvey, W.T., et al. · Nature Medicine · 2022
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6)Husain, M., et al. · New England Journal of Medicine · 2019
- Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS)Weghuber, D., et al. · New England Journal of Medicine · 2022
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)Kosiborod, M.N., et al. · New England Journal of Medicine · 2023
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW)Perkovic, V., et al. · New England Journal of Medicine · 2024
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE)Sanyal, A.J., et al. · New England Journal of Medicine · 2025